The British Pharmacopoeia (BP) and United States Pharmacopeia (USP) have signed a memorandum of understanding which formalises their partnership to strengthen quality standards for medicines.
The two organisations are the official recognised pharmacopoeias in their respective countries, however medicine manufacturers often propose specifications in their applications based on quality standards from international pharmacopoeias. The United States (US) Food and Drug Administration (FDA) have confirmed when medicine sponsors can propose specifications for excipients, medicine substances and medicine products based on standards from the BP, European Pharmacopoeia (EP) and the Japanese Pharmacopoeia (JP).
A group manager for BP and laboratory services at the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has stated that “the work we do will directly benefit from the knowledge sharing and collaboration that will result from this agreement. This will better enable us to serve the needs of our patients and stakeholders across the world and address the future challenges of assuring medicines quality.”
To read more about the formalised partnership between the BP and USP, please click here.